This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AMT 130, AMT130
Description: AMT-130 is a gene therapy that utilizes AAV5 viral vector in which miHTT scaffolds are incorporated using uniQure’s baculovirus-based manufacturing platform. The scaffolds are injected into the central nervous system (CNS) to silence the Huntingtin gene (HTT).
Additional information available to subscribers only: